Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCAINAMIDE HCL vs CIN-QUIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Treatment of documented ventricular arrhythmias (e.g., sustained ventricular tachycardia) that are life-threatening,Off-label: Atrial fibrillation, atrial flutter, supraventricular tachycardia, Wolff-Parkinson-White syndrome
Treatment of atrial fibrillation and flutter,Paroxysmal supraventricular tachycardia,Ventricular arrhythmias,Maintenance of sinus rhythm after cardioversion
For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
Terminal elimination half-life: 2.5-4.7 hours (3 hours typical) in normal renal function; prolonged to 11-20 hours in renal impairment; NAPA half-life 6-8 hours (prolonged in renal failure).
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Hepatic via N-acetyltransferase (NAT2) to N-acetylprocainamide (NAPA); also undergoes hydrolysis to p-aminobenzoic acid.
Metabolized primarily by CYP3A4 to active metabolites (3-hydroxyquinidine and quinidine-N-oxide).
Primarily renal (50-60% unchanged via glomerular filtration and tubular secretion) with 10-30% as N-acetylprocainamide (NAPA) metabolite; minor biliary/fecal (<5%).
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
15-25% bound primarily to alpha-1-acid glycoprotein and albumin.
Approximately 70-80% bound, primarily to alpha-1-acid glycoprotein and, to a lesser extent, albumin.
1.5-2.5 L/kg (approximates total body water; indicates extensive tissue distribution).
Apparent volume of distribution (Vd) is 1.5-2.5 L/kg, indicating extensive tissue distribution.
Oral: 75-95% (immediate-release); IM: 100%; IV: 100%.
Oral bioavailability is approximately 80% in healthy subjects; may be reduced in patients with malaria due to impaired absorption.
Cr Cl >50 m L/min: No adjustment. Cr Cl 10-50 m L/min: Administer every 6-12 hours. Cr Cl <10 m L/min: Administer every 12-24 hours.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <10 m L/min), reduce dose by one-third to one-half (e.g., 324 mg every 8 hours) and monitor for toxicity.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50%. Child-Pugh Class C: Reduce dose by 50-75% or avoid use.
No specific guidelines for Child-Pugh classification; use with caution in severe hepatic impairment (Child-Pugh C) and consider dose reduction by 50% based on clinical response and monitoring of serum levels.
IV: Loading dose: 15 mg/kg over 30-60 minutes, followed by maintenance infusion of 20-80 mcg/kg/min; maximum 2 g/day. Oral: 15-50 mg/kg/day in divided doses every 3-6 hours; maximum 4 g/day.
For malaria: quinine sulfate 10 mg/kg (base) orally every 8 hours for 7 days (maximum 650 mg/dose) in combination with a second agent.
Start at lower end of dosing range due to age-related decreased renal function and increased risk of hypotension and arrhythmias. Monitor renal function and adjust accordingly.
No specific dose adjustments recommended, but start at lower end of dosing range (e.g., 324 mg every 8 hours) due to age-related renal function decline and increased risk of QT prolongation.
Procanamide can cause agranulocytosis, leukopenia, and thrombocytopenia; fatal blood dyscrasias have occurred. Frequent blood counts are recommended.
Quinidine has been associated with thrombocytopenic purpura and may exacerbate arrhythmias (proarrhythmia). It should be used with caution in patients with severe heart disease or preexisting arrhythmias.
May cause lupus erythematosus-like syndrome (especially with slow acetylator phenotype); proarrhythmic effects (torsades de pointes); hypotension; bone marrow suppression; hepatotoxicity; potentiation of neuromuscular blocking agents.
May cause QT prolongation and torsades de pointes, especially in patients with hypokalemia, hypomagnesemia, or bradycardia,Cinchonism (tinnitus, hearing loss, blurred vision, nausea) may occur at high doses,Hepatic toxicity and hypersensitivity reactions (including thrombocytopenia),Monitor serum potassium and magnesium levels,Avoid use with other drugs that prolong QT interval
Complete heart block; second- or third-degree AV block without pacemaker; long QT syndrome; torsades de pointes; known hypersensitivity to procainamide or any component.
Hypersensitivity to quinidine or cinchona alkaloids,Complete AV block without pacemaker,Myasthenia gravis,Digitalis toxicity,History of drug-induced torsades de pointes or QT prolongation
No significant food interactions reported. However, changes in dietary salt intake may affect blood pressure control; avoid excessive caffeine or alcohol as they may trigger arrhythmias. Maintain consistent potassium and magnesium intake; severe electrolyte disbalances can alter drug effect.
Avoid grapefruit and grapefruit juice (increases quinidine exposure). Limit caffeine intake as quinidine may enhance its effects. Maintain adequate potassium and magnesium intake; hypokalemia and hypomagnesemia increase arrhythmia risk.
FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use only if clearly needed. In second and third trimesters, chronic use may be associated with fetal bradycardia, QT prolongation, and neonatal lupus syndrome (transient). Avoid in pregnancy if possible.
CIN-QUIN (quinine) is contraindicated in pregnancy due to teratogenicity. First trimester: risk of congenital malformations (e.g., auditory nerve hypoplasia, limb defects). Second and third trimesters: may cause fetal hypoxia and hypoglycemia; avoid use for malaria prophylaxis. Only in severe falciparum malaria when no alternative exists.
Procainamide and its active metabolite NAPA are excreted into breast milk. Milk-to-plasma ratio is approximately 0.8-1.3. Concentrations in milk can reach therapeutic levels. Potential for adverse effects in nursing infant, including bradycardia and hypotension. Use with caution, monitor infant. AAP recommends avoiding use if possible.
Quinine is excreted into breast milk in small amounts. M/P ratio approximately 0.2-0.5. Limited data suggest low risk to infant; however, monitor for signs of cinchonism (e.g., fever, rash, restlessness).
Pregnancy alters pharmacokinetics: increased volume of distribution may require higher loading doses (25-30% increase). Decreased plasma albumin reduces protein binding, increasing free fraction. Enhanced renal clearance (due to increased GFR) may necessitate more frequent dosing or dose adjustments. Monitor serum concentrations closely. Start with oral doses of 50 mg/kg/day in divided doses, titrate to effect. Intravenous: initial 100 mg every 5 minutes until arrhythmia controlled, then maintenance 2-6 mg/min with adjustments.
Pregnancy increases clearance and volume of distribution of quinine; dose adjustments are not well-defined. For severe malaria, standard dosing (600 mg oral quinine sulfate every 8 hours for 7 days) is used, but therapeutic drug monitoring is recommended.
Procainamide HCL is a Class IA antiarrhythmic used for atrial and ventricular arrhythmias. It can cause lupus-like syndrome, especially in slow acetylators; monitor ANA titers. Renal dose adjustment is critical due to active metabolite N-acetylprocainamide (NAPA) accumulation. Watch for QT prolongation and torsades de pointes; avoid with other QT-prolonging drugs. Administer IV slowly to avoid hypotension; oral loading requires hepatic first-pass consideration.
Cin-Quin is a brand of quinidine, a class Ia antiarrhythmic. Monitor QTc interval; risk of torsades de pointes. Avoid in patients with myasthenia gravis due to neuromuscular blocking effects. Use with caution in hepatic impairment. Can cause cinchonism (tinnitus, headache, nausea).
Take this medication exactly as prescribed; do not double doses if missed.,Report any symptoms of lupus (joint pain, rash, fever, chest pain) immediately.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Tell your doctor all other medications, especially other heart rhythm drugs.,You may need regular blood tests to monitor drug levels and organ function.,Do not stop taking this medicine abruptly; sudden stop may worsen arrhythmia.,If using extended-release tablets, do not crush or chew them.
Take exactly as prescribed; do not skip doses or double up.,Report any rapid or irregular heartbeat, fainting, or severe dizziness.,Avoid grapefruit juice as it can increase quinidine levels.,Do not use with over-the-counter products containing quinine or quinidine.,Tell your doctor if you have liver disease, myasthenia gravis, or low potassium/magnesium.,Quinidine can cause diarrhea; contact your doctor if persistent.,You may experience ringing in the ears or blurred vision; notify your prescriber.
"Procainamide is a class IA antiarrhythmic that is primarily metabolized by N-acetyltransferase (NAT) and also undergoes CYP2D6-mediated metabolism. Midostaurin, a multikinase inhibitor used for FLT3-mutated AML, is metabolized mainly by CYP3A4. Procainamide can inhibit CYP3A4, reducing the clearance and increasing plasma concentrations of midostaurin, potentially leading to enhanced toxicity including QT prolongation, hepatotoxicity, and myelosuppression."
"Procainamide, a Class Ia antiarrhythmic, prolongs the QT interval by blocking cardiac sodium channels and delaying repolarization. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been associated with QT prolongation, possibly via inhibition of cardiac hERG potassium channels. Concomitant use increases the risk of excessive QT prolongation, potentially leading to torsade de pointes and other ventricular arrhythmias."
"Procainamide, a class Ia antiarrhythmic agent, prolongs the QT interval by blocking cardiac sodium and potassium channels. Pentamidine, used for Pneumocystis pneumonia, also prolongs the QT interval through inhibition of the rapid delayed rectifier potassium current (IKr). Concomitant use can cause additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with electrolyte disturbances or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCAINAMIDE HCL vs CIN-QUIN, answered by our medical review team.
PROCAINAMIDE HCL is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.. CIN-QUIN is a Antiarrhythmic (Class Ia) that works by Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCAINAMIDE HCL and CIN-QUIN depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCAINAMIDE HCL is: For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.. The standard adult dose of CIN-QUIN is: Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCAINAMIDE HCL and CIN-QUIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCAINAMIDE HCL is classified as Category A/B. FDA pregnancy category C. Procainamide crosses the placenta. In first trimester, risk of congenital anomalies is not well-studied; animal studies show no teratogenicity but use onl. CIN-QUIN is classified as Category C. CIN-QUIN (quinine) is contraindicated in pregnancy due to teratogenicity. First trimester: risk of congenital malformations (e.g., auditory nerve hypoplasia, limb defects). Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.